Sapanisertib

Uterine Corpus Cancer

National Cancer Institute (NCI)Small moleculePhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 95/ 100

Competitive context

47 Active assets in the Uterine Corpus Cancer cohort.

Asset / Sponsor	Phase	Rating
Carboplatin City of Hope Medical Center	Phase 3	BB
Irinotecan M.D. Anderson Cancer Center	Phase 2	BB
Cabozantinib M.D. Anderson Cancer Center	Phase 2	BB
Nivolumab M.D. Anderson Cancer Center	Phase 2	B
Olaparib National Cancer Institute (NCI)	Phase 2	B

View all 50 →

Same molecule, other indications

Sapanisertib is also rated in:

non-small cell lung carcinomaActive

BB

Indicative · Phase 2

65 / 100

pancreatic neuroendocrine tumorDormant

B

Indicative · Phase 2

61 / 100

plasma cell myelomaActive

B

Indicative · Phase 2

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.